739 related articles for article (PubMed ID: 28919200)
21. Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma.
Chia YL; Yan L; Yu B; Wang B; Barker P; Goldman M; Roskos L
Clin Pharmacol Ther; 2019 Aug; 106(2):383-390. PubMed ID: 30661249
[TBL] [Abstract][Full Text] [Related]
22. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial.
Kliewer KL; Murray-Petzold C; Collins MH; Abonia JP; Bolton SM; DiTommaso LA; Martin LJ; Zhang X; Mukkada VA; Putnam PE; Kellner ES; Devonshire AL; Schwartz JT; Kunnathur VA; Rosenberg CE; Lyles JL; Shoda T; Klion AD; Rothenberg ME
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):803-815. PubMed ID: 37336228
[TBL] [Abstract][Full Text] [Related]
23. Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma.
Chupp G; Lugogo NL; Kline JN; Ferguson GT; Hirsch I; Goldman M; Zangrilli JG; Trudo F
Ann Allergy Asthma Immunol; 2019 May; 122(5):478-485. PubMed ID: 30802500
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma.
Ohta K; Adachi M; Tohda Y; Kamei T; Kato M; Mark Fitzgerald J; Takanuma M; Kakuno T; Imai N; Wu Y; Aurivillius M; Goldman M
Allergol Int; 2018 Apr; 67(2):266-272. PubMed ID: 29128192
[TBL] [Abstract][Full Text] [Related]
25. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.
Nair P; Wenzel S; Rabe KF; Bourdin A; Lugogo NL; Kuna P; Barker P; Sproule S; Ponnarambil S; Goldman M;
N Engl J Med; 2017 Jun; 376(25):2448-2458. PubMed ID: 28530840
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials.
Liu T; Wang F; Wang G; Mao H
Front Med; 2018 Jun; 12(3):340-349. PubMed ID: 29086236
[TBL] [Abstract][Full Text] [Related]
27. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
[TBL] [Abstract][Full Text] [Related]
28. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y;
Int Arch Allergy Immunol; 2016; 169(3):135-45. PubMed ID: 27097165
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
[TBL] [Abstract][Full Text] [Related]
30. Benralizumab for the Prevention of COPD Exacerbations.
Criner GJ; Celli BR; Brightling CE; Agusti A; Papi A; Singh D; Sin DD; Vogelmeier CF; Sciurba FC; Bafadhel M; Backer V; Kato M; Ramírez-Venegas A; Wei YF; Bjermer L; Shih VH; Jison M; O'Quinn S; Makulova N; Newbold P; Goldman M; Martin UJ; ;
N Engl J Med; 2019 Sep; 381(11):1023-1034. PubMed ID: 31112385
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma.
Park HS; Lee SH; Lee SY; Kim MK; Lee BJ; Werkström V; Barker P; Zangrilli JG
Allergy Asthma Immunol Res; 2019 Jul; 11(4):508-518. PubMed ID: 31172719
[TBL] [Abstract][Full Text] [Related]
32. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.
Menzella F; Bargagli E; Aliani M; Bracciale P; Brussino L; Caiaffa MF; Caruso C; Centanni S; D'Amato M; Del Giacco S; De Michele F; Di Marco F; Pastorello EA; Pelaia G; Rogliani P; Romagnoli M; Schino P; Senna G; Vultaggio A; Simoni L; Ori A; Boarino S; Vitiello G; Altieri E; Canonica GW
Respir Res; 2022 Feb; 23(1):36. PubMed ID: 35183167
[TBL] [Abstract][Full Text] [Related]
33. Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment.
Busse WW; Bleecker ER; FitzGerald JM; Ferguson GT; Barker P; Brooks L; Olsson RF; Martin UJ; Goldman M;
J Allergy Clin Immunol; 2021 Jul; 148(1):266-271.e2. PubMed ID: 33609624
[TBL] [Abstract][Full Text] [Related]
34. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.
Sridhar S; Liu H; Pham TH; Damera G; Newbold P
Respir Res; 2019 Jan; 20(1):14. PubMed ID: 30658649
[TBL] [Abstract][Full Text] [Related]
35. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Laviolette M; Gossage DL; Gauvreau G; Leigh R; Olivenstein R; Katial R; Busse WW; Wenzel S; Wu Y; Datta V; Kolbeck R; Molfino NA
J Allergy Clin Immunol; 2013 Nov; 132(5):1086-1096.e5. PubMed ID: 23866823
[TBL] [Abstract][Full Text] [Related]
36. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years.
Korn S; Bourdin A; Chupp G; Cosio BG; Arbetter D; Shah M; Gil EG
J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4381-4392.e4. PubMed ID: 34487870
[TBL] [Abstract][Full Text] [Related]
37. Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report.
Pham DN
J Med Case Rep; 2021 Mar; 15(1):103. PubMed ID: 33673870
[TBL] [Abstract][Full Text] [Related]
38. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
Canonica GW; Harrison TW; Chanez P; Menzella F; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; Garcia Gil E
Allergy; 2022 Jan; 77(1):150-161. PubMed ID: 33978983
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid-dependent asthma in Sweden.
Andersson M; Janson C; Kristensen T; Szende A; Golam S
J Med Econ; 2020 Aug; 23(8):877-884. PubMed ID: 32324093
[No Abstract] [Full Text] [Related]
40. Reductions in eosinophil biomarkers by benralizumab in patients with asthma.
Pham TH; Damera G; Newbold P; Ranade K
Respir Med; 2016 Feb; 111():21-9. PubMed ID: 26775606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
